Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2017 on request of the sponsor.

On 13 November 2013, orphan designation (EU/3/13/1202) was granted by the European Commission to Daiichi Sankyo Development Ltd, United Kingdom, for tivantinib for the treatment of hepatocellular carcinoma.

Key facts

Active substance
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Daiichi Sankyo Development Ltd
Chiltern Place
Chalfont Park
Gerrards Cross
Buckinghamshire SL9 0BG
United Kingdom
Tel. +44 (0)1753 893 600
Fax +44 (0)1753 899 107

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating